Skip to main content
. 2016 Feb 10;107(3):359–368. doi: 10.1111/cas.12859

Figure 1.

Figure 1

I‐branching N‐acetylglucosaminyltransferase (GCNT2) expression correlates with prostate cancer progression. (a) Biosynthetic pathways for I‐antigen. (b) Expression level of GCNT2 was determined using quantitative PCR analysis. (c) Prostate cancer specimens were stained with an anti‐GCNT2 antibody followed by staining with an HRP‐conjugated secondary antibody. Counterstaining was carried out using H&E. GCNT2‐positive cancer cells are indicated in brown. (d) Prostate‐specific antigen (PSA)‐free survival periods were compared between GCNT2‐positive and GCNT2‐negative specimens, and survival analysis was carried out using Kaplan–Meier curves. Scale bar = 200 μm.